Getting to the heart of COX-2 inhibition.
Aspirin protects against heart disease, while COX-2 Inhibitors appear to injure the heart. The studies by [this Issue of Cell Metabolism]) shed light on two distinct prostaglandin receptors contributing to these conflicting cardiovascular effects.
Breyer
Matthew D
MD
Vanderbilt University Medical School, Division of Nephrology, Nashville, TN 37232, USA.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D011464:Epoprostenol / Q000494:pharmacology*; D005355:Fibrosis / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D009206:Myocardium / Q000473:pathology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism*; D011982:Receptors, Prostaglandin / Q000187:drug effects*; D012982:Sodium, Dietary / Q000008:administration & dosage
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D011982:Receptors, Prostaglandin; D012982:Sodium, Dietary; D011464:Epoprostenol; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin